Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Fusion glycoprotein

Fusion glycoprotein

Brief Information

Name:Respiratory syncytial virus F protein
Target Synonym:Protein F,F,Fusion glycoprotein F0
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
FUN-N52H3 Nipah virus Nipah virus Pre-Fusion glycoprotein, His Tag (MALS verified)
ACRO Quality

Part of Bioactivity data

 Fusion glycoprotein BLI

Loaded Anti-Fusion Protein Antibody, Human IgG1 (5B3) on AHC Biosensor, can bind Nipah virus Pre-Fusion glycoprotein, His Tag (Cat. No. FUN-N52H3) with an affinity constant of 8.4 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Fusion glycoprotein MALS images

The purity of Nipah virus Pre-Fusion glycoprotein, His Tag (Cat. No. FUN-N52H3) is more than 90% and the molecular weight of this protein is around 170-200 kDa verified by SEC-MALS.

Synonym Name

Fusion glycoprotein, F protein, F, Nipah virus, Hendra virus


Hendra virus (HeV) and Nipah virus (NiV) are henipaviruses discovered in the mid-to late 1990s that possess a broad host tropism and are known to cause severe and often fatal disease in both humans and animals. HeV and NiV infect host cells through the coordinated efforts of two envelope glycoproteins. The G glycoprotein attaches to cell receptors, triggering the fusion (F) glycoprotein to execute membrane fusion. G is a type II homotetrameric transmembrane protein responsible for binding to ephrinB2 or ephrinB3 (ephrinB2/B3) receptors. F is a homotrimeric type I transmembrane protein that is synthesized as a premature F0 precursor and cleaved by cathepsin L during endocytic recycling to yield the mature, disulfide-linked, F1 and F2 subunits. Upon binding to ephrinB2/B3, NiV G undergoes conformational changes leading to F triggering and insertion of the F hydrophobic fusion peptide into the target membrane. Subsequent refolding into the more stable post-fusion F conformation drives merger of the viral and host membranes to form a pore for genome delivery to the cell cytoplasm.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Nirsevimab Anti-RSV MAb-YTE; Anti-RSV-mAb-D25; MEDI-8897; SP-0232 Approved Aimm Therapeutics, Sanofi, MedImmune Inc Beyfortus EU Respiratory Syncytial Virus Infections Astrazeneca Ab 2022-10-31 Lower Respiratory Tract Infections; Respiratory Syncytial Virus Infections Details
Respiratory syncytial virus immune globulin RSV-IGIV Approved Medimmune RespiGam United States Respiratory Syncytial Virus Infections null 1996-01-01 Respiratory Syncytial Virus Infections Details
Palivizumab ABT-315; MEDI-493 Approved Abbvie Inc, Medimmune Llc Synagis United States Respiratory Syncytial Virus Infections Swedish Orphan Biovitrum Ab (Publ) 1998-06-19 Bronchopulmonary Dysplasia; Respiratory Syncytial Virus Infections; Heart Defects, Congenital; Premature Birth; Infant, Premature, Diseases Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
CPI-RSV-F Vaccine BLB-201 Phase 2 Clinical Respiratory Syncytial Virus Infections Details
Palivizumab biosimilar (mAbxience) Phase 1 Clinical Mabxience Sa Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message